Respiratory syncytial virus vaccine - Vaxine
Latest Information Update: 19 Feb 2023
Price :
$50 *
At a glance
- Originator Vaxine
- Developer University of Pittsburgh; Vaxine
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 06 Feb 2023 Preclinical trials in Respiratory syncytial virus infections (Prevention) in Australia (IM) (Vaxine pipeline, Prior to February 2023)
- 06 Feb 2023 Vaxine plans for clinical trial in Respiratory syncytial virus infections (Vaxine pipeline, February 2023)
- 04 Oct 2022 Pharmacodynamics data from a preclinical study Respiratory syncytial virus infections released by Vaxine